Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Responds to a Times article published on Tuesday saying RedX is looking to list its shares in New York. Redx says it "wishes to clarify that it is not currently in any process relating to a listing in the US, nor any other jurisdiction".

Article quotes Chief Executive Lisa Anson as saying that, to access larger specialist biotechnology investors, "you do need to be ultimately US-listed. So we will look at that as a board." The Times calls the possibility of Redx shares leaving AIM "the latest blow to the City".

Current stock price: 21.10 pence, down 1.9% in London on Wednesday

12-month change: down 56%

By Emma Curzon, Alliance News reporter

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.